Fierce Biotech

Merck, girding for Keytruda cliff, flies toward promising CML asset with $6.7B Terns acquisition

Merck and Terns Pharmaceuticals have agreed to a $6.7 billion all-cash buyout that delivers a prized leukemia asset to the ...

Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B

Merck’s $6.7B Terns deal plus the top 10 U.S.-listed pharma stocks by Seeking Alpha Quant Ratings—bullish picks, caps and ...

Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)

Terns’ lead candidate TERN-701 is an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor c urrently in Phase 1/2 development for ...
GlobalData on MSN

MSD spends $6.7bn to buy Terns Pharmaceuticals in cancer pipeline reinforcement

Terns’ lead candidate has demonstrated “unprecedented data” in chronic myeloid leukaemia, according to analysts.
BioPharma Dive

Merck to buy Terns in $6.7B bet on a ‘differentiated’ leukemia drug

If consummated, the deal would hand Merck a treatment that could challenge Novartis’ fast-selling Scemblix. But the low ...

As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors?

This clinical-stage biotech develops therapies for NASH and obesity, advancing a pipeline of proprietary small-molecule drug candidates.